NGNE
Neurogene Inc

345
Mkt Cap
$352.7M
Volume
339,020.00
52W High
$37.27
52W Low
$6.88
PE Ratio
-5.14
NGNE Fundamentals
Price
$22.77
Prev Close
$26.49
Open
$26.95
50D MA
$25.27
Beta
1.43
Avg. Volume
258,375.70
EPS (Annual)
-$4.28
P/B
1.27
Rev/Employee
$8,644.86
Loading...
Loading...
News
all
press releases
Neurogene (NASDAQ:NGNE) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Neurogene from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Neurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results
Neurogene (NASDAQ:NGNE - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat·7h ago
News Placeholder
Neurogene (NASDAQ:NGNE) Price Target Raised to $70.00 at HC Wainwright
HC Wainwright lifted their price target on Neurogene from $65.00 to $70.00 and gave the company a "buy" rating in a report on Thursday...
MarketBeat·2d ago
News Placeholder
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter...
Business Wire·3d ago
News Placeholder
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive...
Business Wire·4d ago
News Placeholder
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden Registrational Trial in Q4 2025
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the Company...
Business Wire·1mo ago
News Placeholder
Neurogene to Participate in Upcoming Conferences
Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company...
Business Wire·9mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc...
PR Newswire·9mo ago
News Placeholder
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene...
PR Newswire·10mo ago
News Placeholder
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene...
PR Newswire·10mo ago

Latest NGNE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.